We’re glad to see you’re enjoying ReachMD…but how about a more personalized experience?
Expert Answers to Common Questions for Improving the Road to Remission with CAR T-Cell Therapies in Large B-Cell Lymphoma: Considerations for Community Practice
Caron A. Jacobson, MD
Reducing the Burden of Cytomegalovirus in HCT: Optimal Strategy for Prevention
Roy F. Chemaly, MD, MPH
Endometrial Cancer: HER2-Targeted ADCs: A Promising Approach to Address Unmet Needs
Kathleen Moore, MD, MS
Biliary Tract and Pancreatic Cancer: HER2-Targeted ADCs for Gastrointestinal Cancers
Shubham Pant, MD, MBBS
Targeting HER2 Across Advanced Solid Tumors
Susana Banerjee, MBBS, MA, FRCP, PhD
Brad McGregor, MD
ASCO/ESMO 2023 Roundtable: Contextualizing the Latest Advances in HER2-Targeted Therapy for Solid Tumors
The Gut Microbiome: An Evidence-Based Approach to Managing Recurrent C difficile Infection
Colleen Kelly
Andrea Banty, DNP, FNP
Bladder Cancer: HER2-Targeted ADCs for Genitourinary Cancers
Cervical Cancer: HER2-Targeted ADCs – Current Status and Future Directions
Ovarian Cancer: Advances in HER2-Targeted ADCs
Maximizing Benefit with the Expanding Options for Gastric Cancer: Patient Selection and Management
James M. Cleary, MD, PhD
Kathleen Madden, FNP, MSN, AOCNP, APHN
Testing for Solid Tumors: Tissue and Liquid Biopsy Approaches Using NGS Technologies for cfDNA and ctDNA Analysis
Management Strategies for Treatment-Emergent Adverse Events (TEAEs) in HER2-Altered Advanced Solid Tumors
Addressing the Unmet Need in HER2-Positive Advanced Solid Tumors: Exploring Response Rates and Duration of Response
Targeting HER2 in Advanced Solid Tumors: A Comprehensive Understanding of the Rationale and Potential Benefits
Press cancel to remain on ReachMD. Press the link below or the continue button to keep going.
Stay current with the best on medical education